EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Beyond the Lung. Impact of Elexacaftor/Tezacaftor/Ivacaftor on Sinonasal Disease in Children With Cystic Fibrosis

Margaux Petitjean, Alexia Letierce, Anne-Sophie Bonnel, Philippe Reix, Eric Deneuville, Nathalie Stremler, Romain Luscan, Vincent Couloigner, Laurent Mely, Katia Bessaci, Guillaume Labbe, Christophe Marguet und 5 weitere

International Forum of Allergy & Rhinology · 2025-07 · 15 (7) · 715-723

DOI: 10.1002/alr.23557 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Forum of Allergy & Rhinology, online erschienen am 06.03.2025. Verfasst von Margaux Petitjean und 16 weiteren Autor:innen. Beteiligte Einrichtung: Service d'Otorhinolaryngologie, Hôpital Necker Enfants malades, Assistance Publique Hôpitaux de Paris, Université Paris Cité, Paris, France. Hauptthemen laut MEDLINE: Cystic Fibrosis, Aminophenols, Quinolones, Sinusitis. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: CFF, Association Vaincre la Mucoviscidose.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Elexacaftor/tezacaftor/ivacaftor (ETI) is a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) therapy that improves pulmonary function and chronic rhinosinusitis (CRS) in cystic fibrosis (CF) adults with at least one copy of the F508del CFTR mutation. The purpose of this study is to evaluate the impact of ETI on CRS symptoms in children and adolescents with CF.

Methods

The MODUL‐CF observational study is a multicenter prospective cohort study enrolling CF children with at least 1 F508del mutation in France. Subjects answered a standardized questionnaire on nasal obstruction and smell and were invited to complete the Sinus and Nasal Quality of Life Survey (SN‐5) questionnaire prior to ETI therapy and at 1, 3, 6, and 12 months ETI. Part of the cohort underwent sinus computerized tomography (CT) within an ancillary study, scored by the Lund–Mackay CT score (LMKS).

Results

Of 391 subjects, 94 (24.0%) were aged between 6 and 12 years, and 297 were adolescents. Sixty‐four (16.3%) reported nasal obstruction at baseline. One hundred and sixty‐three completed the SN‐5 questionnaire at M0, 181 at M12, and 123 at M0 and M12. Mean SN‐5 global score baseline value was similar to that of a healthy pediatric control cohort. SN‐5 global score, nasal obstruction, sinus infection, and emotion domain subscores improved significantly at 1 month and this was sustained over 12 months. LMKS improved significantly in 43 patients who underwent sinus CT at M0 and M12.

Conclusion

ETI improves sinonasal symptoms and related quality of life (QOL), including emotion domain, in children and adolescents with CF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisAminophenolsQuinolonesSinusitisRhinitisBenzodioxolesIndolesPyrazolesPyridinesPyrrolidinesHumansChildMaleFemaleAdolescentQuality of LifeDrug CombinationsCystic Fibrosis Transmembrane Conductance RegulatorProspective StudiesSurveys and QuestionnairesChloride Channel AgonistsQuinolines

Stichwörter der Autor:innen

CFTRCFTR modulatorschronic rhinosinusitiscystic fibrosisquality of life

Substanzen

AminophenolsQuinolonesBenzodioxolesDrug CombinationsIndolesCystic Fibrosis Transmembrane Conductance RegulatorPyrazolesivacaftorPyridineselexacaftor, ivacaftor, tezacaftor drug combination

Autor:innen und Institutionen

  • Service d'Otorhinolaryngologie, Hôpital Necker Enfants malades, Assistance Publique Hôpitaux de Paris, Université Paris Cité, Paris, France.
  • Qualitystat, Morangis, France.
  • Centre de Référence Maladies Rares Mucoviscidose et Maladies Apparentées, Hôpital Necker Enfants malades, Assistance Publique Hôpitaux de Paris, Groupe Hospitalier Paris Centre, Paris, France.
  • Centre de Ressources et de Compétence pour la Mucoviscidose, Hôpital Mignot, Versailles, France.
  • Centre de Ressources et de Compétence pour la Mucoviscidose, Hospices Civils de Lyon, Lyon, France.
  • Centre de Ressources et de Compétence pour la Mucoviscidose, Centre Hospitalo-Universitaire, Rennes, France.

ORCID-Profile: Isabelle Sermet-Gaudelus

Förderung

  • CFF
  • Association Vaincre la Mucoviscidose

Zitieren

APA

Petitjean, M., Letierce, A., Bonnel, A. S., Reix, P., Deneuville, E., Stremler, N., Luscan, R., Couloigner, V., Mely, L., Bessaci, K., Labbe, G., Marguet, C., Kelly-Aubert, M., Hassani, F., Sermet-Gaudelus, I., Simon, F., & MODUL‐CF Study Group (2025). Beyond the Lung. Impact of Elexacaftor/Tezacaftor/Ivacaftor on Sinonasal Disease in Children With Cystic Fibrosis. International Forum of Allergy & Rhinology, 15(7), 715-723. https://doi.org/10.1002/alr.23557

Vancouver

Petitjean M, Letierce A, Bonnel AS, Reix P, Deneuville E, Stremler N, et al. Beyond the Lung. Impact of Elexacaftor/Tezacaftor/Ivacaftor on Sinonasal Disease in Children With Cystic Fibrosis. International Forum of Allergy & Rhinology. 2025;15(7):715-723. doi:10.1002/alr.23557

BibTeX
@article{Petitjean2025,
  author = {Petitjean, Margaux and Letierce, Alexia and Bonnel, Anne-Sophie and Reix, Philippe and Deneuville, Eric and Stremler, Nathalie and Luscan, Romain and Couloigner, Vincent and Mely, Laurent and Bessaci, Katia and Labbe, Guillaume and Marguet, Christophe and Kelly-Aubert, Mairead and Hassani, Fatiha and Sermet-Gaudelus, Isabelle and Simon, François and MODUL‐CF Study Group, MODUL‐CF Study Group},
  title = {Beyond the Lung. Impact of Elexacaftor/Tezacaftor/Ivacaftor on Sinonasal Disease in Children With Cystic Fibrosis},
  journal = {International Forum of Allergy & Rhinology},
  year = {2025},
  volume = {15},
  number = {7},
  pages = {715--723},
  doi = {10.1002/alr.23557}
}
Kostenlos starten →